A randomized Phase II trial, recently demonstrated that the addition of veliparib to cisplatin significantly improved progression-free survival in patients with BRCA-like metastatic triple-negative breast cancer, but not in patients with non-BRCA-like metastatic breast cancer.31 Considering that only 120 patients in our study had a BRCA1/2 or gPALB2 alteration, HRDsig was able to identify an additional 245 patients who might benefit from PARP inhibitors or platinum-based treatments. This evidence concerns the gene BRCA1 and triple-negative breast carcinoma.